5-Hydroxymethylcytosine profiles of cfDNA are highly predictive of R-CHOP treatment response in diffuse large B cell lymphoma patients.

Hang-Yu ChenWei-Long ZhangLei ZhangPing YangFang LiZe-Ruo YangJing WangMeng PangYun HongChangjian YanWei LiJia LiuNuo XuLong ChenXiu-Bing XiaoYan QinXiao-Hui HeHui LiuHai-Chuan ZhuChuan HeJian LinHong-Mei Jing

Published in: Clinical epigenetics (2021)

Our findings suggest that the 5hmC modifications in cfDNA at the time before R-CHOP treatment are associated with treatment response and that 5hmC-Seal may potentially serve as a clinical-applicable, minimally invasive approach to predict R-CHOP treatment response for DLBCL patients.

Keyphrases

diffuse large b cell lymphoma
end stage renal disease
epstein barr virus
ejection fraction
minimally invasive
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors